Potential effects of omega-3 fatty acids on insulin resistance and lipid profile in maintenance hemodialysis patients a randomized placebo-controlled trial

Iranian Journal of Kidney Diseases

Volumn 10, Issue 5, 2016, Pages 310-318

  Gharekhani, Afshin ^a   Dashti Khavidaki, Simin ^b   Lessan Pezeshki, Mahboob ^b   Khatami, Mohammad Reza ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adiponectin; Hemodialysis; Insulin resistance; Leptin; Lipid profile; Omega 3 fatty acids

Indexed keywords

ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; INSULIN; LEPTIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PLACEBO; TRIACYLGLYCEROL; ADIPOQ PROTEIN, HUMAN; CHOLESTEROL; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BURPING; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEMODIALYSIS; HOMEOSTASIS; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TRIACYLGLYCEROL BLOOD LEVEL; AGED; DIETARY SUPPLEMENT; KIDNEY FAILURE, CHRONIC; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL;

ADIPONECTIN; ADULT; AGED; BLOOD GLUCOSE; BLOOD UREA NITROGEN; C-REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; LEPTIN; MALE; MIDDLE AGED; RENAL DIALYSIS; SINGLE-BLIND METHOD; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84990934117     PISSN: 17358582     EISSN: 17358604     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Foley RN. Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin Dial. 2003;16:111-17.
2. King-Morris K, Ikizler TA. Insulin resistance in patients undergoing peritoneal dialysis: can we improve it?: Editorial to: “the effect of HM-CoA reductase inhibitor on insulin resistance in patients undergoing peritoneal dialysis” by Fa Mee Doh et al. Cardiovasc Drugs Ther. 2012;26:441-43.
3. Becker B, Kronenberg F, Kielstein JT, et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol. 2005;16:1091-8.
4. Shinohara K, Shoji T, Emoto M, et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol. 2002;13:1894-900.
5. Kobayashi S, Maesato K, Moriya H, Ohtake T, Ikeda T. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis. 2005;45:275-80.
6. Hung AM, Ikizler TA. Factors determining insulin resistance in chronic hemodialysis patients. Contrib Nephrol. 2011;171:127-34.
7. DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J. Insulin resistance in uremia. J Clin Invest. 1981;67:563-8.
8. Dashti-Khavidaki S, Gharekhani A, Khatami MR, et al. Effects of omega-3 fatty acids on depression and quality of life in maintenance hemodialysis patients. Am J Ther. 2014;21:275-87.
9. Gharekhani A, Khatami MR, Dashti-Khavidaki S, et al. The effect of omega-3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: a randomized, placebo-controlled clinical trial. Eur J Clin Pharmacol. 2014;70:655-65.
10. Spencer M, Finlin BS, Unal R, et al. Omega-3 fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance. Diabetes. 2013;62:1709-17.
11. Pasarica M, Sereda OR, Redman LM, et al. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes. 2009;58:718-25.
12. Lopez-Huertas E. The effect of EPA and DHA on metabolic syndrome patients: a systematic review of randomized controlled trials. Br J Nutr. 2012;107:S185-94.
13. Hooper L, Thompson RL, Harrison RA, et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev. 2004;4:CD003177.
14. Thies F, Nebe-von-Caron G, Powell JR, Yagoob P, Newsholme EA, Calder PC. Dietary supplementation with gamma-linolenic acid or fish oil decreases T lymphocyte proliferation in healthy older humans. J Nutr. 2001;131:1918-27.
15. Deckelbaum RJ, Worgall TS, Seo T. n-3 fatty acids and gene expression. Am J Clin Nutr. 2006;83:1520S-5S.
16. Mohammadi E, Rafraf M, Farzadi L, asghari-Jafarabadi M, Sabour S. Effects of omega-3 fatty acids supplementation on serum adiponectin levels and some metabolic risk factors in women with polycystic ovary syndrome. Asia Pac J Clin Nutr. 2012;21:511-8.
17. Rösen P, Nawroth PP, King G, Möller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev. 2001;17:189-212.
18. Gillum R. Distribution of serum total homocysteine and its association with diabetes and cardiovascular risk factors of the insulin resistance syndrome in Mexican American men: the Third National Health and Nutrition Examination Survey. Nutr J. 2003;2:6.
19. Reaven GM, Chen YD, Jeppesen J, et al. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest. 1993;92:141-6.
20. Aguilera A, Gonzalez-Espinoza L, Codoceo R, et al. Bowel bacterial overgrowth as another cause of malnutrition, inflammation, and atherosclerosis syndrome in peritoneal dialysis patients. Adv Perit Dial. 2010;26:130-6.
21. Amore A, Coppo R. Immunological basis of inflammation in dialysis. Nephrol Dial Transplant. 2002;17(Suppl 8):16-24.
22. Krotkiewski M, Björntorp P, Sjöström L, Smith U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest. 1983;72:1150-62.
23. Shoelson SE, Lee J, Yuan M. Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity-and dietinduced insulin resistance. Int J Obes Relat Metab Disord. 2003; 27 (Suppl 3):S49-52.
24. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A. 2003;100:7265-70.
25. Saifullah A, Watkins BA, Saha C, Li Y, Moe SM, Friedman AN. Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients-a pilot study. Nephrol Dial Transplant. 2007;22:3561-67.
26. Bowden RG, Jitomir J, Wilson RL, Gentile M. Effects of omega-3 fatty acid supplementation on lipid levels in end stage renal disease patients. J Ren Nutr. 2009;19:259-66.
27. Kooshki A, Taleban FA, Tabibi H, Hedayati M. Effects of omega-3 fatty acids on serum lipids, lipoprotein (a), and hematologic factors in hemodialysis patients. Ren Fail. 2011;33:892-8.
28. Rasic-Milutinovic Z, Perunicic G, Pljesa S, et al. Effects of N-3 PUFAs supplementation on insulin resistance and inflammatory biomarkers in hemodialysis patients. Ren Fail. 2007;29:321-9.
29. Koh KK, Quon MJ, Shin KC, et al. Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia. Atherosclerosis. 2012;220:537-44.
30. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes. 2006;55:1537-45.
31. Axelsson J, Rashid Qureshi A, Suliman ME, et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr. 2004;80:1222-9.
32. Iwabu M, Yamauchi T, Okada-Iwabu M, et al. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature. 2010;464:1313-9.
33. Drechsler C, Krane V, Winkler K, Dekker FW, Wanner C. Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney Int. 2009;76:567-75.
34. Menon V, Li L, Wang X, et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol. 2006;17:2599-606.
35. Loffreda S, Yang SQ, Lin HZ, et al. Leptin regulates proinflammatory immune responses. FASEB J. 1998;12:57-65.
36. Yamagishi SI, Edelstein D, Du XL, Kaneda Y, Guzmán M, Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem. 2001; 276:25096-100.
37. Wolf G, Hamann A, Han DC, et al. Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney Int. 1999;56:860-72.
38. Hung AM, Sundell MB, Egbert P, et al. A comparison of novel and commonly-used indices of insulin sensitivity in African American chronic hemodialysis patients. Clin J Am Soc Nephrol. 2011;6:767-74.
39. Mamaghani F, Zarghami N, Maleki MJ, Pourhassan-Moghaddam M, Hosseinipanah F. Variation of adiponectin levels in normal and obese subjects: possible correlation with lipid profiles. Int J Endocrinol Metab. 2009;3:170-8.
40. Teta D, Maillard M, Halabi G, Burnier M. The leptin/ adiponectin ratio: potential implications for peritoneal dialysis. Kidney Int Suppl. 2008;108:S112-8.
41. Jia T, Huang X, Qureshi AR, et al. Validation of insulin sensitivity surrogate indices and prediction of clinical outcomes in individuals with and without impaired renal function. Kidney Int. 2014;86:383-91.
42. Akinkuolie AO, Ngwa JS, Meigs JB, Djoussé L. Omega-3 polyunsaturated fatty acid and insulin sensitivity: a meta-analysis of randomized controlled trials. Clin Nutr. 2011;30:702-7.
43. Lok CE, Moist L, Hemmelgarn BR, et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA. 2012;307:1809-16.
44. Zhu W, Dong C, Du H, et al. Effects of fish oil on serum lipid profile in dialysis patients: a systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis. 2014;13:1-11.
45. An WS, Lee SM, Son YK, et al. Effect of omega-3 fatty acids on the modification of erythrocyte membrane fatty acid content including oleic acid in peritoneal dialysis patients. Prostaglandins Leukot Essent Fatty Acids. 2012;86:29-34.
46. Martin SS, Khokhar AA, May HT, et al. HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the Lipoprotein Investigators Collaborative. Eur Heart J. 2015;36:22-30.